Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Verubulin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 2/20 | 0.50 |
| ▸ | TUBB known ✓ | P07437 | 2/20 | 0.50 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 2/20 | 0.50 |
| ▸ | TUBA1B known ✓ | P68363 | 2/20 | 0.50 |
| ▸ | TUBA4A known ✓ | P68366 | 2/20 | 0.50 |
| ▸ | TUBB4B known ✓ | P68371 | 2/20 | 0.50 |
| ▸ | TUBB3 known ✓ | Q13509 | 2/20 | 0.50 |
| ▸ | TUBB2A known ✓ | Q13885 | 2/20 | 0.50 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 2/20 | 0.50 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 2/20 | 0.50 |
| ▸ | TUBA1A known ✓ | Q71U36 | 2/20 | 0.50 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 2/20 | 0.50 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 2/20 | 0.50 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 2/20 | 0.50 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 8/20 | 0.80 |
| ▸ | EGFR | P00533 | 6/20 | 0.80 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.80 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3121016 | 0.94 | EGFR (0.70) | KDREGFRPDGFRBCASP1CASP14 | |
| Hydrochloric Acid SCHEMBL3109775 | 0.93 | EGFR (0.69) | KDREGFRPDGFRBCASP1CASP14 | |
| Verubulin SCHEMBL2232326 | 0.89 | KDR (1.00) | KDREGFRPDGFRBHDAC1HDAC8 | |
| Verubulin SCHEMBL29379614 | 0.89 | KDR (1.00) | KDREGFRPDGFRBHDAC1HDAC8 | |
| Verubulin SCHEMBL2395194 | 0.88 | KDR (0.97) | KDREGFRPDGFRBHDAC1HDAC8 | |
| Verubulin SCHEMBL29505369 | 0.88 | KDR (0.97) | KDREGFRPDGFRBHDAC1HDAC8 | |
| Verubulin SCHEMBL3115233 | 0.87 | KDR (0.64) | KDREGFRPDGFRBHDAC1HDAC8 | |
| SCHEMBL3110573 | 0.83 | EGFR (0.70) | KDREGFRPDGFRBHDAC1HDAC8 | |
| SCHEMBL2262157 | 0.83 | PDE5A (0.59) | KDREGFRPDGFRB | |
| SCHEMBL3114980 | 0.82 | PDGFRB (0.54) | KDREGFRPDGFRBHDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | claimed |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | claimed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | claimed |
| JP-2007524637-A | — | — | 2007-08-30 | — | — | JP | claimed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | claimed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | claimed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | TUBB4A 162/4885TUBB 371/4885TUBA3C 360/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | TUBB4A 155/4885TUBB 332/4885TUBA3C 327/4885 |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | TUBB4A 162/4885TUBB 371/4885TUBA3C 360/4885 |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | TUBB4A 162/4885TUBB 371/4885TUBA3C 360/4885 |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | TUBB4A 162/4885TUBB 371/4885TUBA3C 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.